Mouse Models Chart
| Mouse Cancer Model | Gene | Developer | Genetic Background | Western Consortium | Eastern Consortium |
| Breast Cancer 1 | Neu | Chodosh | FVB | Yes* | Yes |
| Breast Cancer 2 | PyMT | Kemp | FVB | Yes | No |
| Lung Cancer 3 | EGFR | Varmus | NA | Yes* | Yes |
| Lung Cancer 4 | K-iras/p53 | Kemp | A/J | Yes | Yes |
| Prostate Cancer 5 6 | TAg | Greenberg | B6 (alias TRAMP) | Yes* | No |
| Prostate Cancer 7 | PTEN | Wu (via Nelson) | B6 | Yes | No |
| Ovarian Cancer 8 | TAg | Connelly | B6 | Yes | No |
| Ovarian Cancer 9 | p53/Pten | Dinulescu/Jacks | NA | No | Yes |
| Colon Cancer 10 | Apc1638 | Kucherlapati | B6 | Yes | No |
| Colon Cancer 11 | APC min | Dove | B6 | Yes | Yes |
| Colon Cancer 12 | D580 | Kucherlapati | 129/B6 mixed | No | Yes |
| Skin Cancer 13 | H-ras | Kemp | NIH (alias p19 skin) | Yes | No |
| Pancreatic Cancer 14 | Kras and INK/ARF | DePinho | NA | No | Yes |
*Shared Mouse Models among Western Consortia Testing Labs
Citation of Original Mouse Model Publication
1Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.
Moody S, Sarkisian C, Hahn K, Gunther E, Pickup S, Dugan K, Innocent N, Cardiff R, Schnall M, and Chodosh L.
Cancer Cell International, 2002 May; 2: 451-461.
[ View Abstract ]
2Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.
Lin E, Jones J, Li P, Zhu L, Whitney K, Muller W, and Pollard, J.
American Journal of Pathology. 2003 November; 163: 2113-2126.
[ View Abstract ]
3Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
Politi K, Zakowski M, Fan P, Schonfeld E, Pao W, and Varmus H.
Genes and Development. 2006 June 1; 20(11): 1496-510.
[ View Abstract ]
4Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice.
Horio, Y, Chen, A, Rice, P, Roth, J., Malkinson A, and Schrump, D.
Molecular Carcinogenesis. 1996 December;17(4): 217-23.
[ View Abstract ]
5Prostate cancer in a transgenic mouse.
Greenberg N, DeMayo F, Finegold M, Medina D, Tilley W, Aspinall J, Cunha G, Donjacour A, Matusik R, and Rosen J.
Proceedings of the National Academy of Sciences, USA. 1995 May; 92: 3439-3443.
[ View Abstract ]
6Metastatic prostate cancer in a transgenic mouse.
Gingrich J, Barrios R, Morton R, Boyce B, DeMayo F, Finegold M, Angelopoulou R, Rosen J, and Greenberg N.
Cancer Research. 1996 Janury; 56: 4096-4102.
[ View Abstract ]
7Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.
Podsypanina K, Ellenson L, Nemes A, Gu J, Tamura M, Yamada K, Cardo C, Catoretti G, Fisher P, and Parsons R.
Proceedings of the National Academy of Sciences, USA. 1999 February; 96: 1563-1568.
[ View Abstract ]
8Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
Connolly D, Bao R, Nikitin A, Stephens K, Poole T, Hua X, Harris S, Vanderhyden B, and Hamilton T.
Cancer Research. 2003 March; 63(6):1389-97.
[ View Abstract ]
9Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.
Dinulescu D, Ince T, Quade B, Shafer S, Crowley D, and Jacks T.
Nature Medicine. 2005 January; 11(1): 63-70.
[ View Abstract ]
10A chain termination mutation in the mouse Apc gene results in intestinal tumors.
Fodde R, Edelmann K, Yang C, Leeuwen C, Carlson B, Renault C, Bruekel E, Alt M, Lipkin P, Khan M, and Kucherlapati R.
Proceedings of the National Academy of Sciences, USA. 1994 September; 91: 8969-8973.
[ View Abstract ]
11ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias.
Moser A, Mattes E, Dove W, Lindstrom M, Haag J, and Gould M.
Proceedings of the National Academy of Sciences, USA. 1993 October; 90: 8977-8981.
[ View Abstract ]
12Adenomatous polyposis coli (APC) is required for normal development of skin and thymus.
Kuraguchi M, Wang X, Bronson R, Rothenberg R, Ohene-Baah N, Lund J, Kucherlapati M, Maas R, and Kucherlapati R.
PLOS Genetics. 2006 July 28. [E-pub ahead of print].
[ View Abstract ]
13p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.
Kelly-Spratt K, Gurley K, Yasui Y, and Kemp C.
PLOS Biology. 2004 August; 2: E242.
[ View Abstract ]
14Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.
Aguirre A, Bardeesy N, Sinha M, Lopez L, Tuveson D, Horner J, Redston M, and DePinho R.
Genes and Development. 2003 December; 17: 3112-3126.
[ View Abstract ]
